As Shreehas Tambe readies to take charge of the unified Biocon Group following the integration of Biocon Biologics, the company is entering what he calls a “capacity‑rich, demand‑heavy” phase—one ...

Biocon’s Q3 revenue and EBITDA missed estimates, while profit rose sharply on a low base despite a ₹293 crore exceptional loss. The company also moved to fully integrate Biocon Biologics.

Biocon Ltd has received US FDA approval for its complex formulation Liraglutide Injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda). The drug-device combination is indicated ...

Motilal Oswal is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 450 in its research report dated 3, 2026.

By Rishika Sadam Feb 16 (Reuters) - Biocon is aiming for high-double-digit percentage revenue growth as the Indian ...

Biocon Limited on Thursday reported a 5.7-fold year-on-year (YoY) increase in consolidated net profit attributable to the ...

Biocon Q3 FY26 Results: Revenue Up 11% YoY to ₹4,290 Cr 📈 | MCap 59,195.55 Cr • Total revenue reached ₹4,290 Cr, up 11% year ...

According to Axis Securities, the reduction in reciprocal taxes is incrementally positive for Indian pharmaceutical companies, particularly those with significant exposure to the US market, ...

Biocon, an Indian pharmaceutical firm, is planning a global launch of generic weight-loss drugs, aiming for high double-digit percentage revenue growth.

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...